Nucana Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated June 18, 2025, reports other events and supplemental risk factors for Nucana Plc, a foreign issuer headquartered in Edinburgh, United Kingdom. The filing addresses significant executive leadership changes and potential listing risks on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. It focuses on capital structure and share counts as of June 16, 2025:
- Ordinary Shares Outstanding: 9,540,891,147 shares of £0.0004 each.
- American Depository Shares (ADSs) Outstanding: 381,295,861 ADSs (each representing 25 ordinary shares).
- Shareholders of Record: 15.
- Equity Compensation: The Board approved options to purchase an aggregate of 3,478,076,733 ordinary shares for officers, employees, consultants, and directors. Exercise prices range from par value to market value at the date of grant, with vesting periods up to 4 years.
Material Changes
Executive Leadership Changes (Effective June 18, 2025):
- Hugh S. Griffith (CEO): Taking a leave of absence due to health reasons; expected to return later in the year.
- Andrew Kay (Chairman): Appointed Executive Chairman and will act as the principal executive officer during Mr. Griffith's leave.
- Ian Webster (Director of Finance): Appointed Interim Chief Financial Officer; will continue to serve as principal financial officer.
Guidance, Risks, and Contingencies
Delisting and Trading Halt Risks:
- Public Interest Concerns: The May 2025 offering may trigger an immediate trading halt or delisting under Nasdaq Listing Rule 5101 due to public interest concerns regarding the dilutive nature of the transaction.
- Warrant Provisions: Series A and Series B ADS Purchase Warrants contain exercise price reset and share combination provisions. Series B Warrants include a "zero exercise price" option that could significantly increase the number of issuable ADSs.
- Minimum Bid Price: The Company faces delisting risks if the ADS closing price falls below $1.00 for 30 consecutive trading days. A grace period of 180 days may be granted, but no grace period is available if the price falls to $0.10 or less for 10 consecutive days.
- Consequences of Delisting: Potential loss of investment value, reduced liquidity, difficulty in raising capital, and potential trading on over-the-counter (OTC) markets subject to "penny stock" regulations.
Forward-Looking Statements: Management notes that actual results may differ materially due to global political and economic conflicts and general market conditions.
Investor Verification Checklist
- Verify the current trading status of Nucana ADSs on The Nasdaq Capital Market to confirm no trading halt has been imposed.
- Monitor the daily closing price of ADSs to assess compliance with the $1.00 minimum bid price requirement.
- Review the specific terms of the May 2025 offering and the Series A and Series B Warrants to understand the potential dilution impact.
- Confirm the timeline for CEO Hugh S. Griffith's return and the operational stability under the interim leadership structure.
- Check for any subsequent filings regarding Nasdaq deficiency letters or hearing requests related to listing standards.